IFNA2 and COVID-19: Although these findings cannot be considered a formal demonstration of the efficacy of IFNα2a therapy for COVID-19, the case report showed that a single subcutaneous injection of Peg-IFNα2a was safe and effective in the patient with impaired production of type I IFNs associated with a predisposition to severe COVID-19 [109].